However, based on the clinical universality of muti-drug combination therapy, the mechanism of BNIP3-AMPK-ENO2 axis in HCC will need to be verified in future clinical studies to definitively link cell competition with HCC lenvatinib resistance. Here, ENO2 is linked to hepatocellular carcinoma.